The ALS Association

Research Webinars and Videos

Upcoming Webinars

Patients’ Needs and Requests with Respect to Assistive Communication Technologies

Speaker: Terry Heiman-Patterson, M.D., Professor and Vice Chair of the Department of Neurology at Drexel University College of Medicine

Date: Thursday, June 16, 2016
Time: 12:00 p.m. EDT
Login: Register Now

Disaggregase Modalities for ALS

Speaker: James Shorter, M.A., Ph.D., Associate Professor, Department of Biochemistry & Biophysics, Perelman School of Medicine, University of Pennsylvania
The misfolding and aggregation of specific proteins in degenerating motor neurons and glia is a pathological hallmark of ALS. In this webinar, I will present our efforts to uncover therapeutic protein disaggregases that reverse these protein misfolding and aggregation events.

Date: Tuesday, July 26, 2016
Time: 4:00 p.m. EDT
Login: Register Now


The ALS Association/Northeast ALS Consortium PALS Webinars

PALS Webinar: Clinical Trial of Ezogabine (Retigabine) on Motor Neuron Excitability in ALS

Speaker: Brian Wainger, MD, PhD, Massachusetts General Hospital
Dr. Brian Wainger will discuss the rationale and design of the study, describe the patient population to be recruited and what is entailed by participating in the study as well as provide a brief update of the ongoing study.

Date: Wednesday, May 25, 2016
Time: 2:00 p.m. EDT
Login: Register Now

PALS Webinar: ALS Clinical Trial Pipeline Series - Spring 2016

Date: Wednesday, Jun 8, 2016
Time: 2:00 p.m. EDT
Login: Register Now


Past Webinars:

Business Plans for ALS Assistive Technologies

Speaker: Bob Koppes, MSc, M.B.A., Accenture Management Consulting
> View summary of this webinar
> Watch this webinar

New Therapeutic Approaches for ALS Based on RNA Binding Proteins

Speakers:
Benjamin Wolozin, M.D., Ph.D., Professor of Pharmacology and Neurology, Boston University School of Medicine, Co-founder Aquinnah Pharmaceuticals
Glenn Larsen, Ph.D., CEO, Aquinnah Pharmaceuticals Inc
> View summary of this webinar
> Watch this webinar

Progress in Therapy Development for C9ort72 ALS/FTD

Speaker: Clotilde Lagier-Tourenne, M.D., Ph.D.
> View summary of this webinar

How can we use predictions of individual ALS patient disease progressions to improve ALS clinical trials?

Speaker: David L. Ennist, PhD, MBA
> Watch this webinar
> View summary of this webinar

Iron Horse Diagnostics : Developing Tests to Aid Rapid ALS Diagnosis and Monitor Disease Progression

Speaker: Dr. Robert Bowser, PhD, President, Iron Horse Diagnostics, Inc., Dr. Andreas Jeromin, PhD, Chief Scientific Officer, Iron Horse Diagnostics, Inc.
> Watch this webinar
> View summary of this webinar

Developing Therapy Based on the Root Cause of ALS

Speaker: Dr. Phillip Wong, Professor of Pathology at Johns Hopkins University School of Medicine
> View summary of this webinar

Epidemiology Studies in ALS

Speaker: Bjorn Oskarsson, M.D., University of California. Davis
> View summary of this webinar

ALS Association Reserach Update

Speaker: Dr. Lucie Bruijn, Chief Scientist, The ALS Association
> View summary of this webinar

The CReATe Consortium

Speaker: Dr. Michael Benatar, University of Miami Health System
> View summary of this webinar

The Neurocollaborative: Therapy Development for ALS

Speaker: Steven Finkbeiner, M.D., Ph.D., Professor, Departments of Neurology and Physiology, University of California, San Francisco
> View recording of this webinar

The Neurocollaborative: Therapy Development for ALS

Speaker: Don W. Cleveland, Head, Laboratory for Cell Biology, Ludwig Institute for Cancer Research;  Distinguished Professor and Chair, Dept. of Cellular and Molecular Medicine, Univ. of California, San Diego
> View summary and recording of this webinar

Imaging Inflammation in the Brain May Speed Development of New Treatments

Speaker: Nazem Atassi, MD, MMSc, Neurological Clinical Research Institute (NCRI), Massachusetts General Hospital
> View summary and recording of this webinar

Induced Pluripotent Stem Cells to Model and Treat ALS: A New ALS Association Funded Core Facility at Cedars-Sinai

Speaker: Clive Svendsen, Ph. D., Director, The Board of Governors Regenerative Medicine Institute at Cedars Sinai Medical Center
> View summary and recording of this webinar

A Whole Genome Approach to ALS Genetics at the New York Genome Center

Speaker: Hemali Phatnani, Ph.D., The New York Genome Center
> View summary and recording of this webinar

Research Opportunities as a Result of Ice Bucket Challenge Funds

Speaker: Lucie Bruihn, MBA, PhD
> View summary and recording of this webinar

Exome-Wide Rare Variant Analysis Identifies a Novel Gene Associated with Familial ALS

Speaker: John Landers, Ph.D., Professor, University of Massachusetts Medical School
>View summary and recording of this webinar

An Update on ALS Research

Speaker: Lucie Bruijn, M.B.A., Ph.D., Chief Scientist, The ALS Association
> View summary and recording of this webinar

The role of biomarkers in studying pre-symptomatic ALS

Speaker: Michael Benatar, M.D., Ph.D., Associate Professor of Neurology at the University of Miami
> View summary and recording of this webinar

A Pilot Clinical Trial of mGluR5 Brain PET Imaging in ALS – a potential biomarker to assist in diagnosis and monitoring disease progression

Speaker: Lyle W. Ostrow, M.D., Ph.D., Johns Hopkins School of Medicine
> View summary and recording of this webinar

Canine ALS Model Provides Unique Opportunity for Therapy Testing

Speaker: Joan Coates, D.V.M.
> View summary and recording of this webinar

Telemedicine for ALS

Speaker: Ed Kasarskis, M.D., ALSA Certified Center Director
> View summary and recording of this webinar

An Overview of ALS Research

Speaker: Lucie Bruijn, PhD, Chief Scientist, The ALS Association
> View summary and recording of this webinar

Altered protein quality control: How cells metabolize mutant and damaged proteins, but fail to keep up in ALS

Speaker: Heather D. Durham, PhD, Professor, Department of Neurology and Neurosurgery and Montreal Neurological Institute, McGill University
> View summary of this webinar

Altered Ribostasis: the role of perturbed RNA metabolism in ALS and related diseases

Speaker: Paul Taylor, M.D., Ph.D., St. Jude Children's Research Hospital
> View summary and recording of this webinar

Insights into Motor Neuron Disease from Drosophilia

Speaker: Brian D. McCabe, Ph.D. Assistant Professor, Columbia University, New York, N.Y.
> View summary and recording of this webinar

Staging System for ALS Should Help Clinical Decision-making

Speaker: Ammar Al-Chalabi, M.D.
Professor of Neurology and Complex Disease Genetics, and Director of King’s MND Care and Research Centre at King’s College in London
> View summary and recording of this webinar

C9ORF72 – the role of RNA toxicity in ALS

Speaker: Rita Sattler, Ph.D.
Assistant Professor, Dept. of Neurology, Brain Science Institute
Principal Scientist, NeuroTranslational Drug Discovery Program
Johns Hopkins School of Medicine
> View recording of this webinar

An Overview of ALS Research

Speaker: Dr. Lucie Bruijn
> View summary and recording of this webinar

MusK Agonists as a treatment for ALS

Speaker: Steven Burden, Ph.D., NYU Langone Medical Center
> View summary and recording of this webinar

Diaphragm Pacing System Will Be Tested in Nationwide Clinical Trial

Speaker: Dr. Kirsten Gruis
> View summary and recording of this webinar

Phase I Stem Cell Trial Leads to Phase II, and a New Immunosuppression Trial

Speaker: Dr. Jonathan Glass
> View summary and recording of this webinar

Telemedicine May Offer ALS Patients Multidisciplinary Care in Their Own Homes

Speaker: Dr. James Berry
During a recent ALS Association research webinar, James Berry, M.D., M.P.H., discussed how telemedicine may soon be used to provide care to those with ALS without leaving their home.
> View summary and recording of this webinar

A Year in Review

Speaker: Lucie Bruijn, Ph.D., The ALS Association
> View summary of this webinar

Progress in Developing Biomarkers for ALS Will Speed Clinical Trials

Speaker: Andreas Jeromin, Ph.D.
> View summary of this webinar

The Role of the Immune System in ALS

Speaker: Howard Weiner, MD, Brigham and Women's Hospital
> View summary of this webinar

Can Vaccination Stop SOD Protein's Toxic Effects?

Speaker: Janice Robertson, Ph.D.
View summary of this webinar

Discoveries Give New Meaning to "Familial" and "Sporadic" ALS

Speaker: Michael Benatar, M.D.
> View Summary of this webinar

C9ORF72: Another Vital Piece of the Molecular Jigsaw Puzzle

Speaker: Dr. Chris Shaw, 2012 Sheila Essey Award recipient
> View recorded webinar

Stem Cells, Growth Factors and ALS - Separating the Hope from the Hype

Speaker: Clive Svendsen, Ph.D., Director, Cedars-Sinai Regenerative Medicine Institute

> View summary of this webinar

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=1a0273b4d34964bc096e456be3eb48ad

TDP-43 Proteinopathies in ALS-Dementia

Speaker: Professor Virginia Lee, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA

> View summary of this webinar

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=82e2a67b0b5206872745098a40076f44

Mechanisms and Therapeutic Approaches for TDP-43 Proteinopathies

Leonard Petrucelli, Ph.D. Chair of Neuroscience
Mayo Clinic, Jacksonville, Florida

> View summary of this webinar

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=d46a2f36073ae80aa61a5a1615a7bc2f

Topic: Autophagy as a therapeutic target for ALS

Stephen Finkbeiner, M.D., Ph.D. from the Gladstone Institute, UCSD

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=47c11c81755b572cc30a1090abe799c8

> View summary of this webinar

Understanding the Connection:
ALS and Frontotemporal Lobar Dementia

Presented by Catherine Lomen-Hoerth, MD, neurologist and director of the ALS Center at UCSF Medical Center in San Francisco, California.
> View summary of this webinar

For ALS Mouse Models, Maine Lab is the Core Resource

Presented by: Cathleen Lutz, PhD, Jackson Laboratories
In a recent webinar The ALS Association sponsored, Cathleen Lutz, Ph.D., Associate Director of the Genetic Resource Science Repository at Jackson Laboratories, spoke about the Lab’s work to develop, maintain and distribute ALS mice.

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=f572c85acfe3c0b24ee22bfd73f7a6ab

> View summary of this webinar

Research Update Webinar on the ALS Mouse Repository at Jackson Laboratories

> View recorded webinar

Rosa Rademakers, PhD. and Bryan Traynor, MD.

A newly-discovered mutation is the most common known genetic cause of familial ALS and also accounts for some sporadic ALS cases. Researchers now have new clues about ALS and familial frontotemporal dementia (FTD). Hear Rosa Rademakers, PhD, and Bryan Traynor, MD discuss the implications of the new research.

Rosa Rademakers is with the Department of Neuroscience at the Mayo Clinic in Jacksonville, Florida. Her research is centered around the molecular genetic analyses of neurodegenerative diseases with a main focus on frontotemporal dementia (FTD) and ALS.

Bryan Traynor is Chief of the Neuromuscular Diseases Research Group in the Laboratory of Neurogenetics at the National Institutes of Health (NIA) and an adjunct faculty member of the Neurology Department, Johns Hopkins.

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=d5cf52113c46da44164e7cd9571dc23e

> View Summary of this Webinar

Dr. Teepu Siddique

Professor of Neurology, Northwestern University.

Dr. Siddique was the senior researcher for the new gene linked to familial ALS involved in the processing of accumulated proteins, Ubiquillin-2. He has dedicated most of his career to neurological disorders such as ALS. Dr. Siddique will be speaking of the discovery of the Ubiquillin-2 and its impact on the future of ALS research.

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=50c171f2719a0110bc12a1f2138b0ec1

> View Summary of this Webinar

TREAT ALS/NEALS Clinical Network

Dr. Merit Cudkowicz
Professor of Neurology, Harvard Medical School

Dr. Cudkowicz chairs the Northeast ALS Consortium (NEALS) where they are dedicated to developing and implementing clinical trials and other research studies focused on the understanding of ALS and improving the care of those living with the disease.

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=4b167047796403a0144aeafaeec1297b

> View Summary of this Webinar

Exercise Clinical Trial for ALS

Nicholas Maragakis, M.D.
Johns Hopkins School of Medicine, Baltimore, MD

Despite decades of discussion over the potential benefit or harm of exercise in ALS, no study has compared these two forms of exercise, resistance and endurance, with the current standards of ALS care—stretching and range of motion exercise. The ALS Association is funding Dr’s Nicholas Maragakis and Merit Cudkowicz to address these questions in a randomized, controlled study with the long term goal of establishing a larger efficacy study and eventually a consensus statement on the potential benefits (or detriments) of exercise in this neurodegenerative disease.

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=5785dfba8ecfb75a70949b6f876a9691

Understanding the relationships between gene variations and patterns of ALS. The ALSoD database.

Ammar Al-Chalabi, MD
MRC Center for Neurodegenerative research
Insititute of Psychiatry
London, UK

Keeping up with the rapidly changing field of ALS genetics is difficult. New genes thought to cause ALS with varying levels of scientific support are reported almost every month, and even for those that are widely regarded as being true ALS genes, the exact variations within them and how they relate to disease may be difficult to understand. One way to overcome this problem is by collecting all the scientific reports and unpublished genetic information in one place, combining information about the clinical picture with genetics to see if new patterns emerge. The ALS Online Database (ALSoD) found at http://alsod.iop.kcl.ac.uk currently records information on 74 possible ALS genes with tools for analysis and summaries of the relationships between those genes and patterns of ALS.

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?RCID=210f88405fbb6e88f7abbe7227353ba2

Related Documents:

Summary: Online Database of ALS Genes

Keeping Up with Genetic Discoveries in ALS

The role of TDP43 in ALS

Tom Maniatis, Ph.D.
Columbia Medical School, New York, NY

Identification of mutations in TDP43 linked to familial ALS has opened up new avenues for research. Using novel technologies, Dr. Maniatis’s laboratory is attempting to understand how TDP43 causes ALS, enabling the identification of new approaches to treat ALS.

> View Summary of this Webinar

Electrical Impedance Myography as a Biomarker for ALS

Dr. Seward Rutkove
Beth Israel Deaconess Medical Center

Dr. Seward Rutkove’s biomarker, a method called electrical impedance myography (EIM), sensitively measures the flow of a tiny, painless, electrical current through muscle tissue.  As the disease progresses, ALS patients’ muscles atrophy, and the more their muscles weaken and shrink, the greater the change detected as the current moves through the muscle.  By comparing the size and speed of the electrical current as it passes through healthy and diseased tissue, EIM can accurately measure the progression of the disease.

> View archived webinar at https://alsa.webex.com/alsa/ldr.php?AT=pb&SP=MC&rID=62567427&rKey=4e32152d4abb5a59

Exome sequencing and identification of mutations in VCP linked to familial ALS

Bryan Traynor, M.D.
National Institute of Aging, Bethesda, MD

Exome sequencing is a new technique, which allows researchers to rapidly sequence the 1% of the human genome that codes proteins; this is where 85% of the mutations causing familial ALS lies.  Using this technology, Dr. Traynor identified a new gene, valosin-containing protein (VCP), which is linked to familial ALS.

> View summary of this webinar at http://www.alsa.org/news/archive/whole-exome-sequencing.html

Using Induced Pluripotent Stem Cells to Identify New Treatments for ALS

Ashkan Javaherian, Ph.D.
iPierian, San Francisco, CA

Adult skin cells can be manipulated to generate induced pluripotent stem cells to produce motor neurons and astrocytes, cells at risk in ALS.  The ALS Association has awarded a one-year grant to iPierian to support the identification of a “cellular phenotype,” which represents differences in motor neurons or astroglial cells derived from ALS patients, versus healthy controls.  This phenotype would be the basis for drug screening to identify potential disease-modifying drug candidates for ALS.

> View summary of this webinar

Powered by Blackbaud
nonprofit software